Bloody stools in children with atypical hemolytic uremic syndrome (aHUS) may indicate the simultaneous presence of inflammatory bowel disease (IBD), three case studies report. These findings raise questions about the connection between aHUS and its associated defects in the complement system, and the gut inflammation characteristic of…
Rare genetic variants in complement genes have been associated with atypical hemolytic uremic syndrome (aHUS) linked with anti-factor H autoantibodies (anti-FHs), recent research shows. Moreover, the study adds evidence that common infections contribute to this type of aHUS in genetically predisposed individuals. These observations explain why there is a…
Soliris (eculizumab), started before or just after a kidney transplant, works against graft loss and improves long-term kidney function — potentially avoiding dialysis — in people with atypical hemolytic uremic syndrome (aHUS) who were diagnosed before this surgery, a registry study reports. But…
Russia has approved for patient use the first biosimilar of Soliris (eculizumab), a monoclonal antibody for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The product was created by the…
A novel blood test may help monitor disease activity in patients with atypical hemolytic uremic syndrome (aHUS), as well as those at risk for relapse, a preliminary study reports. The test measures the ability of a person’s serum to activate complement factor C5b-9, which is usually higher in…
Get regular updates to your inbox.